An immunotherapeutic strategy combining a dendritic cell vaccine with adoptive T-cell therapy has shown clinical benefit in patients with advanced stage III and IV ovarian cancer, according to data from two phase I trials presented at the AACR meeting. Dendritic cells were isolated from patients and a vaccine was prepared by exposing the patients' dendritic cells to their own tumour tissue. Of the 19 patients treated with the vaccine, eight had no measurable disease and one achieved complete remission.